Faster, Smarter, Confident: What the Right Analytical Partner Delivers
Drug discovery today is entering one of its most exciting chapters. Biologics, biosimilars, ADCs, TPDs, and other complex modalities are reshaping what is therapeutically possible, and the science has never been more promising. But as molecular complexity grows, so does the analytical burden that sits behind every program decision, and that is where many promising molecules lose critical time.
Rising regulatory expectations, high infrastructure investment requirements, and a limited pool of analytical scientists experienced in complex modalities are real constraints that compound at every stage of development. Most programs don’t stall because the science is wrong. They stall because the analytical strategy wasn’t built for the complexity they’re running.
The Right Infrastructure Changes Everything
When you are working across a portfolio of peptides, ADCs, oligonucleotides, and PROTACs simultaneously, a generalist analytical setup simply won’t keep pace. Chromophore and non-chromophore molecules demand different detection strategies because their structural properties determine how they absorb light and respond to standard UV detection, and mismatched methods mean missed data or false confidence.
From there, absolute stereochemistry assignment becomes the next critical hurdle, increasingly important in today’s complex modalities, yet requiring specialized capability that most teams simply don’t have in-house. And when chiral resolution gets queued behind competing priorities, it can quietly add weeks to a timeline that nobody budgeted for. Each of these challenges builds on the last, and without the right analytical infrastructure, the cumulative delay can be significant.
Purpose-Built Capability for Complex Modalities
Complex modalities demand more than standard analytical tools. They require infrastructure purpose-built for the specific characterization challenges that peptides, ADCs, oligonucleotides, and PROTACs bring to the table, backed by deep experience with these complex modalities. Aragen delivers exactly that.
Aragen’s NMR infrastructure, with 23 instruments spanning 400 and 500 MHz with cryoprobe technology enables definitive structure elucidation, stereochemical assignment, and structural identification of unknown compounds, going beyond routine characterization. For chiral molecules, parallel chiral screening across SFC and HPLC configurations, combined with more than 15 columns for chiral purification, means faster method development and confident, reproducible results. In addition, Aragen offers library sample purification capabilities and salt content estimation using the CAD method.
Aragen is one of the first CROs in India to adopt SFC and today delivers prep-SFC throughput at multi-kilogram scale per month, a capability that becomes non-negotiable as programs scale. The VCD (Vibrational Circular Dichroism) offering, the only such capability among Indian CROs, adds absolute configuration confidence that increasingly sophisticated regulatory expectations demand.
Scientific Integrity Built into the Process
Aragen performs independent Final QC for all final compounds, a practice that removes ambiguity from purity specifications, builds regulatory confidence, and ensures every program decision is grounded in data you can trust. Layered on top is E-sample, Aragen’s proprietary digital tool that connects sample tracking, analytical workflows, and data management, reducing cycle time and human error at every step. As the industry shifts toward digital-first models that streamline operations and elevate data quality, sponsors increasingly prioritize partners who can support end-to-end data integration, not just sample turnaround.
Accelerating Discovery Through Integrated Analytical Expertise
An integrated analytical strategy brings together instrumentation, specialized expertise, and high-throughput workflows to deliver fast, reproducible results at every stage. At Aragen, this integration operates across three interconnected pillars.
Independent Final QC verifies purity and structural identity, delivering greater confidence in every data set that informs screening decisions.
Digital connectivity through E-sample, integrated with Empower and ACD Spectrus®, enabling seamless sample tracking, data processing, and spectral interpretation.
Open-access LC-MS adds to this by giving chemists quick, direct access to results without workflow interruption.
Choosing the Right Analytical Partner Has Never Mattered More
It is no longer about finding a vendor who can turn around samples. It is about finding a partner who thinks like an extension of your own team, one who brings the right science, the right scale, and the right speed to every program decision, at every stage of drug discovery.
If your pipeline involves complex modalities and the pressure to make faster, more confident decisions, Aragen’s analytical chemistry capabilities are built precisely for that.
Speak to Aragen’s analytical experts and find out how your programs can move faster with greater confidence.
